pharma · COVID-19 · Poliomyelitis
Sinovac Research and
Sinovac Research and Development Co.,
SINOVAC BIOTECH (BANGLADESH) is a pharma organization headquartered in Dhaka, CN. Primary therapeutic focus areas include COVID-19, Poliomyelitis, Influenza, Hand, Foot and Mouth Disease, Varicella. NovaPharmaNews links
Dhaka, CN HQ
2022 Founded
9 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Dhaka, CN
- Founded
- 2022
- Employees
- 9
- Programs
- 115
- Drugs
- 54
- Patents
- 0
pandemic influenza vaccine (H5N1 strain NIBRG-14)
Phase 1 · mab · Pandemic Influenza Vaccine
pandemic influenza vaccine (H5N1 strain NIBRG-14) for Pandemic Influenza Vaccine is a Phase 1 program (mab) at Sinovac Research and Development Co., with 1 ClinicalTrials.gov record(s).
Internal code PRO-PanFlu-1002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sinovac Research and Development Co.,
- Phase
- Phase 1
- Modality
- mab
- Indication
- Pandemic Influenza Vaccine
- Status
- completed
- Trials
- 1